FOXM1: From cancer initiation to progression and treatment

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1819, Issue 1, 2012, Pages 28-37

  Koo, Chuay Yeng ^a   Muir, Kyle W ^a   Lam, Eric W F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cancer; Chemotherapy; FOXM1; Function; Regulation

Indexed keywords

CISPLATIN; CYCLIN A2; CYCLIN B1; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; GELATINASE A; GELATINASE B; IMATINIB; LAPATINIB; PACLITAXEL; PROTEIN TYROSINE PHOSPHATASE; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR FOXO; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CYTOSTASIS; CYTOTOXICITY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EMBRYO DEVELOPMENT; GENE EXPRESSION; GERM CELL TUMOR; HUMAN; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LYMPHOMA; MICROTUBULE ASSEMBLY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SARCOMA; TESTIS CANCER; TRANSCRIPTION REGULATION;

CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS;

EID: 81055137232     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2011.09.004     Document Type: Review

References (116)

1. Korver W., Roose J., Heinen K., Weghuis D.O., de Bruijn D., van Kessel A.G., Clevers H. The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization. Genomics 1997, 46:435-442.
2. Laoukili J., Stahl M., Medema R.H. FoxM1: at the crossroads of ageing and cancer. Biochim. Biophys. Acta 2007, 1775:92-102.
3. Yao K.M., Sha M., Lu Z., Wong G.G. Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J. Biol. Chem. 1997, 272:19827-19836.
4. Kalinina O.A., Kalinin S.A., Polack E.W., Mikaelian I., Panda S., Costa R.H., Adami G.R. Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions. Oncogene 2003, 22:6266-6276.
5. Kalin T.V., Wang I.C., Ackerson T.J., Major M.L., Detrisac C.J., Kalinichenko V.V., Lyubimov A., Costa R.H. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 2006, 66:1712-1720.
6. Kim I.M., Ackerson T., Ramakrishna S., Tretiakova M., Wang I.C., Kalin T.V., Major M.L., Gusarova G.A., Yoder H.M., Costa R.H., Kalinichenko V.V. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006, 66:2153-2161.
7. Liu M., Dai B., Kang S.H., Ban K., Huang F.J., Lang F.F., Aldape K.D., Xie T.X., Pelloski C.E., Xie K., Sawaya R., Huang S. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006, 66:3593-3602.
8. Madureira P.A., Varshochi R., Constantinidou D., Francis R.E., Coombes R.C., Yao K.M., Lam E.W. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J. Biol. Chem. 2006, 281:25167-25176.
9. Wang Z., Banerjee S., Kong D., Li Y., Sarkar F.H. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007, 67:8293-8300.
10. Yoshida Y., Wang I.C., Yoder H.M., Davidson N.O., Costa R.H. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 2007, 132:1420-1431.
11. Chan D.W., Yu S.Y., Chiu P.M., Yao K.M., Liu V.W., Cheung A.N., Ngan H.Y. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J. Pathol. 2008, 215:245-252.
12. Teh M.T., Wong S.T., Neill G.W., Ghali L.R., Philpott M.P., Quinn A.G. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 2002, 62:4773-4780.
13. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
14. Gemenetzidis E., Bose A., Riaz A.M., Chaplin T., Young B.D., Ali M., Sugden D., Thurlow J.K., Cheong S.C., Teo S.H., Wan H., Waseem A., Parkinson E.K., Fortune F., Teh M.T. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 2009, 4:e4849.
15. Teh M.T., Gemenetzidis E., Chaplin T., Young B.D., Philpott M.P. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol. Cancer 2010, 9:45.
16. Green M.R., Aya-Bonilla C., Gandhi M.K., Lea R.A., Wellwood J., Wood P., Marlton P., Griffiths L.R. Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosom. Cancer 2011, 50:313-326.
17. Huynh K.M., Soh J.W., Dash R., Sarkar D., Fisher P.B., Kang D. FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells. J. Cell. Physiol. 2011, 226:194-204.
18. Nakamura S., Hirano I., Okinaka K., Takemura T., Yokota D., Ono T., Shigeno K., Shibata K., Fujisawa S., Ohnishi K. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis 2010, 31:2012-2021.
19. Pilarsky C., Wenzig M., Specht T., Saeger H.D., Grutzmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004, 6:744-750.
20. Uddin S., Ahmed M., Hussain A., Abubaker J., Al-Sanea N., AbdulJabbar A., Ashari L.H., Alhomoud S., Al-Dayel F., Jehan Z., Bavi P., Siraj A.K., Al-Kuraya K.S. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am. J. Pathol. 2011, 178:537-547.
21. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., Tsunoda T., Furukawa Y., Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001, 61:2129-2137.
22. Francis R.E., Myatt S.S., Krol J., Hartman J., Peck B., McGovern U.B., Wang J., Guest S.K., Filipovic A., Gojis O., Palmieri C., Peston D., Shousha S., Yu Q., Sicinski P., Coombes R.C., Lam E.W. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int. J. Oncol. 2009, 35:57-68.
23. Costa R.H., Kalinichenko V.V., Major M.L., Raychaudhuri P. New and unexpected: forkhead meets ARF. Curr. Opin. Genet. Dev. 2005, 15:42-48.
24. Kretschmer C., Sterner-Kock A., Siedentopf F., Schoenegg W., Schlag P.M., Kemmner W. Identification of early molecular markers for breast cancer. Mol. Cancer 2011, 10:15.
25. Wang I.C., Chen Y.J., Hughes D., Petrovic V., Major M.L., Park H.J., Tan Y., Ackerson T., Costa R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 2005, 25:10875-10894.
26. Laoukili J., Kooistra M.R., Bras A., Kauw J., Kerkhoven R.M., Morrison A., Clevers H., Medema R.H. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 2005, 7:126-136.
27. Wonsey D.R., Follettie M.T. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 2005, 65:5181-5189.
28. Kalinichenko V.V., Major M.L., Wang X., Petrovic V., Kuechle J., Yoder H.M., Dennewitz M.B., Shin B., Datta A., Raychaudhuri P., Costa R.H. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004, 18:830-850.
29. Gusarova G.A., Wang I.C., Major M.L., Kalinichenko V.V., Ackerson T., Petrovic V., Costa R.H. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest. 2007, 117:99-111.
30. Major M.L., Lepe R., Costa R.H. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol. Cell. Biol. 2004, 24:2649-2661.
31. Laoukili J., Alvarez M., Meijer L.A., Stahl M., Mohammed S., Kleij L., Heck A.J., Medema R.H. Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. Mol. Cell. Biol. 2008, 28:3076-3087.
32. Ma R.Y., Tong T.H., Cheung A.M., Tsang A.C., Leung W.Y., Yao K.M. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J. Cell Sci. 2005, 118:795-806.
33. Fu Z., Malureanu L., Huang J., Wang W., Li H., van Deursen J.M., Tindall D.J., Chen J. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat. Cell Biol. 2008, 10:1076-1082.
34. Zeng J., Wang L., Li Q., Li W., Bjorkholm M., Jia J., Xu D. FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. J. Pathol. 2009, 218:419-427.
35. Li S.K., Smith D.K., Leung W.Y., Cheung A.M., Lam E.W., Dimri G.P., Yao K.M. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. J. Biol. Chem. 2008, 283:16545-16553.
36. Gemenetzidis E., Elena-Costea D., Parkinson E.K., Waseem A., Wan H., Teh M.T. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res. 2010, 70:9515-9526.
37. Wang I.C., Zhang Y., Snyder J., Sutherland M.J., Burhans M.S., Shannon J.M., Park H.J., Whitsett J.A., Kalinichenko V.V. Increased expression of FoxM1 transcription factor in respiratory epithelium inhibits lung sacculation and causes Clara cell hyperplasia. Dev. Biol. 2010, 347:301-314.
38. Tompkins D.H., Besnard V., Lange A.W., Keiser A.R., Wert S.E., Bruno M.D., Whitsett J.A. Sox2 activates cell proliferation and differentiation in the respiratory epithelium. Am. J. Respir. Cell Mol. Biol. 2011, 45:101-110.
39. Xie Z., Tan G., Ding M., Dong D., Chen T., Meng X., Huang X., Tan Y. Foxm1 transcription factor is required for maintenance of pluripotency of P19 embryonal carcinoma cells. Nucleic Acids Res. 2010, 38:8027-8038.
40. Myatt S.S., Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 2007, 7:847-859.
41. Balli D., Zhang Y., Snyder J., Kalinichenko V.V., Kalin T.V. Endothelial cell-specific deletion of transcription factor FoxM1 increases urethane-induced lung carcinogenesis. Cancer Res. 2011, 71:40-50.
42. Wang I.C., Meliton L., Tretiakova M., Costa R.H., Kalinichenko V.V., Kalin T.V. Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene 2008, 27:4137-4149.
43. Ahmad A., Wang Z., Kong D., Ali S., Li Y., Banerjee S., Ali R., Sarkar F.H. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res. Treat. 2010, 122:337-346.
44. Ye H., Kelly T.F., Samadani U., Lim L., Rubio S., Overdier D.G., Roebuck K.A., Costa R.H. Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol. Cell. Biol. 1997, 17:1626-1641.
45. Kalin T.V., Wang I.C., Meliton L., Zhang Y., Wert S.E., Ren X., Snyder J., Bell S.M., Graf L., Whitsett J.A., Kalinichenko V.V. Forkhead Box m1 transcription factor is required for perinatal lung function. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19330-19335.
46. Ustiyan V., Wang I.C., Ren X., Zhang Y., Snyder J., Xu Y., Wert S.E., Lessard J.L., Kalin T.V., Kalinichenko V.V. Forkhead box M1 transcriptional factor is required for smooth muscle cells during embryonic development of blood vessels and esophagus. Dev. Biol. 2009, 336:266-279.
47. Ueno H., Nakajo N., Watanabe M., Isoda M., Sagata N. FoxM1-driven cell division is required for neuronal differentiation in early Xenopus embryos. Development 2008, 135:2023-2030.
48. Korver W., Schilham M.W., Moerer P., van den Hoff M.J., Dam K., Lamers W.H., Medema R.H., Clevers H. Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor Trident. Curr. Biol. 1998, 8:1327-1330.
49. Krupczak-Hollis K., Wang X., Kalinichenko V.V., Gusarova G.A., Wang I.C., Dennewitz M.B., Yoder H.M., Kiyokawa H., Kaestner K.H., Costa R.H. The mouse Forkhead Box m1 transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. Dev. Biol. 2004, 276:74-88.
50. Ackermann Misfeldt A., Costa R.H., Gannon M. Beta-cell proliferation, but not neogenesis, following 60% partial pancreatectomy is impaired in the absence of FoxM1. Diabetes 2008, 57:3069-3077.
51. Tan Y., Raychaudhuri P., Costa R.H. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell. Biol. 2007, 27:1007-1016.
52. Kalinichenko V.V., Gusarova G.A., Tan Y., Wang I.C., Major M.L., Wang X., Yoder H.M., Costa R.H. Ubiquitous expression of the forkhead box M1B transgene accelerates proliferation of distinct pulmonary cell types following lung injury. J. Biol. Chem. 2003, 278:37888-37894.
53. Wang X., Hung N.J., Costa R.H. Earlier expression of the transcription factor HFH-11B diminishes induction of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte entry into S-phase following carbon tetrachloride liver injury. Hepatology 2001, 33:1404-1414.
54. Ye H., Holterman A.X., Yoo K.W., Franks R.R., Costa R.H. Premature expression of the winged helix transcription factor HFH-11B in regenerating mouse liver accelerates hepatocyte entry into S phase. Mol. Cell. Biol. 1999, 19:8570-8580.
55. C.T. Karadedou, A.R. Gomes, J. Chen, M. Petkovic, K.K. Ho, A.K. Zwolinska, A. Feltes, S.Y. Wong, K.Y. Chan, Y.N. Cheung, J.W. Tsang, J.J. Brosens, U.S. Khoo, E.W. Lam, FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer, Oncogene (in press), doi:. [Electronic publication ahead of print]. doi:10.1038/onc.2011.368.
56. Zhang Y., Zhang N., Dai B., Liu M., Sawaya R., Xie K., Huang S. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008, 68:8733-8742.
57. Li Q., Zhang N., Jia Z., Le X., Dai B., Wei D., Huang S., Tan D., Xie K. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009, 69:3501-3509.
58. Overall C.M., Dean R.A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 2006, 25:69-75.
59. van Kempen L.C., Coussens L.M. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002, 2:251-252.
60. Dai B., Kang S.H., Gong W., Liu M., Aldape K.D., Sawaya R., Huang S. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 2007, 26:6212-6219.
61. Chandran U.R., Ma C., Dhir R., Bisceglia M., Lyons-Weiler M., Liang W., Michalopoulos G., Becich M., Monzon F.A. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7:64.
62. Park H.J., Gusarova G., Wang Z., Carr J.R., Li J., Kim K.H., Qiu J., Park Y.D., Williamson P.R., Hay N., Tyner A.L., Lau L.F., Costa R.H., Raychaudhuri P. Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol. Med. 2011, 3:21-34.
63. Martin M., Villar A., Sole-Calvo A., Gonzalez R., Massuti B., Lizon J., Camps C., Carrato A., Casado A., Candel M.T., Albanell J., Aranda J., Munarriz B., Campbell J., Diaz-Rubio E. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann. Oncol. 2003, 14:833-842.
64. E.B.C.T.C.G.(EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
65. Alvarez R.H. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 2010, 12(Suppl 2):S1.
66. Palmieri C., Krell J., James C.R., Harper-Wynne C., Misra V., Cleator S., Miles D. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat. Rev. Clin. Oncol. 2010, 7:561-574.
67. Haber D.A., Bell D.W., Sordella R., Kwak E.L., Godin-Heymann N., Sharma S.V., Lynch T.J., Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:419-426.
68. Astsaturov I., Cohen R.B., Harari P. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert. Rev. Anticancer. Ther. 2006, 6:1179-1193.
69. Birnbaum A., Ready N. Gefitinib therapy for non-small cell lung cancer. Curr. Treat. Options Oncol. 2005, 6:75-81.
70. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001, 7:2958-2970.
71. Roszkiewicz F., Garidi R., Vaida I., Royer B., Parcelier A., Marolleau J.P., Damaj G. Tyrosine kinase inhibitors and solid tumours: case report and review of the literature. Pharmacology 2009, 84:38-41.
72. Scotto K.W., Biedler J.L., Melera P.W. Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 1986, 232:751-755.
73. Myatt S.S., Lam E.W. Targeting FOXM1. Nat. Rev. Cancer 2008, 8:242.
74. Ho K.K., Anderson A.A., Rosivatz E., Lam E.W., Woscholski R., Mann D.J. Identification of cyclin A2 as the downstream effector of the nuclear phosphatidylinositol 4,5-bisphosphate signaling network. J. Biol. Chem. 2008, 283:5477-5485.
75. Lam E.W., Francis R.E., Petkovic M. FOXO transcription factors: key regulators of cell fate. Biochem. Soc. Trans. 2006, 34:722-726.
76. Gomes A.R., Brosens J.J., Lam E.W. Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008, 7:3133-3136.
77. Brosens J.J., Wilson M.S., Lam E.W. FOXO transcription factors: from cell fate decisions to regulation of human female reproduction. Adv. Exp. Med. Biol. 2009, 665:227-241.
78. Kajihara T., Jones M., Fusi L., Takano M., Feroze-Zaidi F., Pirianov G., Mehmet H., Ishihara O., Higham J.M., Lam E.W., Brosens J.J. Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. Mol. Endocrinol. 2006, 20:2444-2455.
79. Sunters A., Fernandez de Mattos S., Stahl M., Brosens J.J., Zoumpoulidou G., Saunders C.A., Coffer P.J., Medema R.H., Coombes R.C., Lam E.W. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 2003, 278:49795-49805.
80. Sunters A., Madureira P.A., Pomeranz K.M., Aubert M., Brosens J.J., Cook S.J., Burgering B.M., Coombes R.C., Lam E.W. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res. 2006, 66:212-220.
81. Hui R.C., Francis R.E., Guest S.K., Costa J.R., Gomes A.R., Myatt S.S., Brosens J.J., Lam E.W. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol. Cancer Ther. 2008, 7:670-678.
82. McGovern U.B., Francis R.E., Peck B., Guest S.K., Wang J., Myatt S.S., Krol J., Kwok J.M., Polychronis A., Coombes R.C., Lam E.W. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol. Cancer Ther. 2009, 8:582-591.
83. Krol J., Francis R.E., Albergaria A., Sunters A., Polychronis A., Coombes R.C., Lam E.W. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol. Cancer Ther. 2007, 6:3169-3179.
84. Fernandez de Mattos S., Essafi A., Soeiro I., Pietersen A.M., Birkenkamp K.U., Edwards C.S., Martino A., Nelson B.H., Francis J.M., Jones M.C., Brosens J.J., Coffer P.J., Lam E.W. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol. Cell. Biol. 2004, 24:10058-10071.
85. Birkenkamp K.U., Essafi A., van der Vos K.E., da Costa M., Hui R.C., Holstege F., Koenderman L., Lam E.W., Coffer P.J. FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. J. Biol. Chem. 2007, 282:2211-2220.
86. Essafi A., Fernandez de Mattos S., Hassen Y.A., Soeiro I., Mufti G.J., Thomas N.S., Medema R.H., Lam E.W. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005, 24:2317-2329.
87. Fernandez de Mattos S., Villalonga P., Clardy J., Lam E.W. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol. Cancer Ther. 2008, 7:3237-3246.
88. Delpuech O., Griffiths B., East P., Essafi A., Lam E.W., Burgering B., Downward J., Schulze A. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol. Cell. Biol. 2007, 27:4917-4930.
89. Wilson M.S., Brosens J.J., Schwenen H.D., Lam E.W. FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr. Drug Targets 2011, 12:1256-1266.
90. Carr J.R., Park H.J., Wang Z., Kiefer M.M., Raychaudhuri P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res. 2010, 70:5054-5063.
91. Sunayama J., Tsuruta F., Masuyama N., Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J. Cell Biol. 2005, 170:295-304.
92. Essers M.A., Weijzen S., de Vries-Smits A.M., Saarloos I., de Ruiter N.D., Bos J.L., Burgering B.M. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004, 23:4802-4812.
93. Coluccia M., Natile G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med. Chem. 2007, 7:111-123.
94. Sedletska Y., Giraud-Panis M.J., Malinge J.M. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr. Med. Chem. Anticancer Agents 2005, 5:251-265.
95. Kwok J.M., Peck B., Monteiro L.J., Schwenen H.D., Millour J., Coombes R.C., Myatt S.S., Lam E.W. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res. 2010, 8:24-34.
96. Sinha B.K., Politi P.M. Anthracyclines. Cancer Chemother. Biol. Response Mod. 1990, 11:45-57.
97. Millour J., de Olano N., Horimoto Y., Monteiro L.J., Langer J.K., Aligue R., Hajji N., Lam E.W. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol. Cancer Ther. 2011, 10:1046-1058.
98. Barsotti A.M., Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 2009, 28:4295-4305.
99. Hui R.C., Gomes A.R., Constantinidou D., Costa J.R., Karadedou C.T., Fernandez de Mattos S., Wymann M.P., Brosens J.J., Schulze A., Lam E.W. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol. Cell. Biol. 2008, 28:5886-5898.
100. Tsai W.B., Chung Y.M., Takahashi Y., Xu Z., Hu M.C. Functional interaction between FOXO3a and ATM regulates DNA damage response. Nat. Cell Biol. 2008, 10:460-467.
101. Yalcin S., Zhang X., Luciano J.P., Mungamuri S.K., Marinkovic D., Vercherat C., Sarkar A., Grisotto M., Taneja R., Ghaffari S. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. J. Biol. Chem. 2008, 283:25692-25705.
102. Park H.J., Carr J.R., Wang Z., Nogueira V., Hay N., Tyner A.L., Lau L.F., Costa R.H., Raychaudhuri P. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009, 28:2908-2918.
103. van Erp N.P., Gelderblom H., Guchelaar H.J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat. Rev. 2009, 35:692-706.
104. Carter C.A., Kelly R.J., Giaccone G. Small-molecule inhibitors of the human epidermal receptor family. Expert Opin. Investig. Drugs 2009, 18:1829-1842.
105. Nencioni A., Cea M., Garuti A., Passalacqua M., Raffaghello L., Soncini D., Moran E., Zoppoli G., Pistoia V., Patrone F., Ballestrero A. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PLoS One 2010, 5:e9024.
106. Brunner N., Zugmaier G., Bano M., Ennis B.W., Clarke R., Cullen K.J., Kern F.G., Dickson R.B., Lippman M.E. Endocrine therapy of human breast cancer cells: the role of secreted polypeptide growth factors. Cancer Cells 1989, 1:81-86.
107. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2002, 2:101-112.
108. Gapinski P.V., Donegan W.L. Estrogen receptors and breast cancer: prognostic and therapeutic implications. Surgery 1980, 88:386-393.
109. Knight W.A., Osborne C.K., Yochmowitz M.G., McGuire W.L. Steroid hormone receptors in the management of human breast cancer. Ann. Clin. Res. 1980, 12:202-207.
110. Lykkesfeldt A.E., Larsen J.K., Christensen I.J. Cell cycle analysis of estrogen stimulation and antiestrogen inhibition of growth of the human breast cancer cell line MCF-7. Breast Cancer Res. Treat. 1986, 7(Suppl):S83-S90.
111. Millour J., Constantinidou D., Stavropoulou A.V., Wilson M.S., Myatt S.S., Kwok J.M., Sivanandan K., Coombes R.C., Medema R.H., Hartman J., Lykkesfeldt A.E., Lam E.W. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010, 29:2983-2995.
112. Cicatiello L., Scafoglio C., Altucci L., Cancemi M., Natoli G., Facchiano A., Iazzetti G., Calogero R., Biglia N., De Bortoli M., Sfiligoi C., Sismondi P., Bresciani F., Weisz A. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J. Mol. Endocrinol. 2004, 32:719-775.
113. Horimoto Y., Hartman J., Millour J., Pollock S., Olmos Y., Ho K.K., Coombes R.C., Poutanen M., Mäkelä S.I., El-Bahrawy M., Speirs V., Lam E.W. ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer. Am. J. Pathol. 2011, 179:1148-1156.
114. Radhakrishnan S.K., Bhat U.G., Hughes D.E., Wang I.C., Costa R.H., Gartel A.L. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006, 66:9731-9735.
115. Kwok J.M., Myatt S.S., Marson C.M., Coombes R.C., Constantinidou D., Lam E.W. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol. Cancer Ther. 2008, 7:2022-2032.
116. Bhat U.G., Halasi M., Gartel A.L. FoxM1 is a general target for proteasome inhibitors. PLoS One 2009, 4:e6593.